The increasing popularity of glucagon-like peptide-1 (GLP-1) medications, fueled by social media trends and endorsements, is raising safety concerns due to the rise of counterfeit drugs and unqualified providers. The WHO has warned about the spread of falsified products that threaten patient safety.
and enjoy FREE RM10 & when you sign up using code VERSAMM10 with min. cash of RM100 today! T&Cs apply.KUALA LUMPUR, Feb 10 — Often referred to as a ‘miracle drug’, glucagon-like peptide-1 medications have seen a surge in popularity in recent years, fuelled by social media testimonials, influencer endorsements and viral before-and-after photos.
For many people, the appeal is obvious — a once-weekly injection that suppresses appetite and delivers weight loss results that typically take months of dieting and exercise. But what began as a tightly regulated diabetes drug is now being sold — often cheaply and sometimes illegally — by unqualified providers, as GLP-1 medications are increasingly viewed as lifestyle solutions rather than serious medical interventions. In some cases, counterfeit GLP-1 drugs are illegally marketed as authentic but instead contain harmful or incorrect ingredients, or have too little, too much or no active ingredient at all. In fact, demand for GLP-1 therapies has grown so rapidly that the World Health Organization issued anto its members last December, warning of the spread of falsified and substandard products that threaten patient safety and public trust.A quick fix Simply put, GLP-1 medications mimic a hormone released by the small intestine after a meal, effectively “tricking” the brain and stomach.Clinical trials have shown that GLP-1 medications can help patients lose weight and better control blood sugar, potentially reducing the risk of heart attacks, strokes and other serious health complications. Because of their effectiveness in treating obesity and diabetes, the WHO added GLP-1 therapies to its Essential Medicines List for managing type 2 diabetes in high-risk groups in September last year. However, according to the UK’s Medicines and Healthcare products Regulatory Agency , the most common side effects of GLP-1 medications are digestive issues, including constipation, diarrhoea, loss of appetite, nausea and vomiting.Common brand names for GLP-1 drugs include Wegovy, Ozempic, Mounjaro and Saxenda. Most GLP-1 drugs are self-administered via injection under the skin — typically in the abdomen, thigh or upper arm — either once weekly or daily, with doses ranging from 0.25 milligrams up to 2.4 mg.Locally, the growing off-label use and aggressive marketing of GLP-1 medications for quick or cosmetic weight loss — particularly among individuals who are neither diabetic nor clinically obese — has alarmed medical practitioners. Malaysian Medical Association president Datuk Dr Thirunavukarasu Rajoo said the drugs are intended for specific medical conditions and must only be prescribed by trained physicians following proper consultation, clinical evaluation and monitoring. “The use of GLP-1 drugs without medical supervision, including those obtained without a valid prescription, carries potential health risks and may not be suitable for every patient, even among those with type 2 diabetes or obesity. “MMA strongly advises the public against purchasing GLP-1 drugs online, as they risk buying counterfeit, unsafe or improperly stored products,” he said in a statement to Malay Mail. Dr Thirunavukarasu Rajoo said individuals considering GLP-1 treatment should consult a medical doctor for proper assessment and obtain the medication through legitimate medical channels. — Picture courtesy of MMA Dr Thirunavukarasu warned that GLP-1 medications could be misused when taken without medical supervision, particularly by people using them for cosmetic weight loss rather than legitimate medical reasons. He said the drugs are intended for long-term management of conditions such as type 2 diabetes and obesity, and should only be prescribed after doctors determine they are appropriate as part of a comprehensive care plan. “When GLP-1 drugs are started or stopped without proper clinical assessment, follow-up and lifestyle support, patients may experience rebound weight gain and other health complications. “This can lead to a cycle of repeated or prolonged use without addressing the underlying health issues,” he said. He added that GLP-1 therapies should form part of a structured, long-term treatment plan that includes dietary changes, lifestyle modifications and regular medical monitoring, rather than being viewed as short-term or cosmetic solutions. As demand for GLP-1 medications has risen in recent years, Dr Thirunavukarasu said the surge — particularly for weight loss use — had at one point put pressure on supplies, including for patients with type 2 diabetes who rely on them. However, he added that the situation has since improved, with availability largely stabilising as supply chains adjusted and prescribing practices became more structured. “MMA continues to emphasise the importance of appropriate prescribing to ensure patients with clear medical indications, especially those with diabetes, are able to access these medications without disruption,” he said.
GLP-1 Medications Weight Loss Counterfeit Drugs WHO Diabetes
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Education Ministry Prepares for Surge in Year One Admissions for Six-Year-OldsThe Education Ministry is gearing up for a significant increase in Year One pupil enrollment from next year, anticipating a positive response from parents. Online registration opens February 15th, with a focus on mapping schools, optimizing existing facilities, and preparing for higher intake, particularly in urban areas. The ministry will also recruit more teachers and construct new classrooms to accommodate the growing number of students.
Read more »
Singapore Sees Investment Surge in 2025 as Chinese Companies Flock to the City-StateSingapore experienced a rise in investments in 2025, driven by Chinese companies. The manufacturing sector, particularly semiconductors, contributed significantly, despite a decrease in job creation. The EDB data indicates a shift in investment patterns, with China surpassing the US in fixed asset commitments.
Read more »
Asia rallies as Japan shares surge to record peakKAJANG: A residential unit on the eighth floor of an apartment building here, used to store a large quantity of firecrackers, was destroyed in a fire on Sunday night (Feb 8).
Read more »
Coordinated Indian AI disinformation, including ‘Hindu genocide’ claims, threatens Bangladesh electionsDHAKA, Feb 9 — Voters in Bangladesh elect a new government on February 12, but analysts warn their choice is threatened by a coordinated surge of disinformation, much of which...
Read more »
Wings out, protein bowls in: The GLP-1 crowd is rewriting Super Bowl food cultureSANTA CLARA, Feb 9 — Pizza, pasta or Chinese take-out used to be the go-to Super Bowl spread for Marla Senzon’s family — until the Florida retiree began taking a GLP‑1...
Read more »
OpenAI's ChatGPT Sees Growth Surge, Prepares New Model LaunchOpenAI CEO Sam Altman announced ChatGPT is exceeding 10% monthly growth and plans to launch an updated model. The company, facing competition from rivals like Anthropic and Google, is also focusing on revenue generation through measures like in-app advertisements.
Read more »